Research graph
References from Tafamidis: is it truly a game changer for transthyretin amyloid cardiomyopathy?. Local targets link to admitted publications; unresolved targets remain external evidence.
2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee
10.1016/j.jacc.2022.11.022 · 2023 · External reference
Redefining the Epidemiology of Cardiac Amyloidosis. A Systematic Review and Meta-Analysis of Screening Studies
10.1002/ejhf.2532 · 2022 · External reference
Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis
2020 · External reference
Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement
10.1093/eurheartj/ehx350 · 2017 · External reference
Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis
10.1016/0140-6736(93)93127-m · 1993 · External reference
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
10.1056/nejmoa1805689 · 2018 · External reference
Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review
10.1016/j.jacc.2019.04.003 · 2019 · External reference
Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics
10.1126/science.1079589 · 2003 · External reference
Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release
10.1016/j.jacc.2018.07.092 · 2018 · External reference
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
10.1007/s40120-016-0040-x · 2016 · External reference
Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy
10.1016/0960-8966(96)88826-2 · 1996 · External reference
Transmission of Systemic Transthyretin Amyloidosis by Means of Domino Liver Transplantation
10.1056/nejm200506023522219 · 2005 · External reference
Trans-Suppression of Misfolding in an Amyloid Disease
10.1126/science.1062245 · 2001 · External reference
Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story
10.2147/dddt.s289772 · 2021 · External reference
Tafamidis for transthyretin familial amyloid polyneuropathy
10.1212/wnl.0b013e3182661eb1 · 2012 · External reference
Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis
10.1007/s12265-013-9512-x · 2013 · External reference
Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis
10.1007/s12265-015-9613-9 · 2015 · External reference
Tafamidis in transthyretin amyloid cardiomyopathy: Effects on transthyretin stabilization and clinical outcomes
10.1161/circheartfailure.113.000890 · 2015 · External reference
Long‐term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage
10.1002/ejhf.3696 · 2025 · External reference
Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association
10.1161/cir.0000000000000792 · 2020 · External reference
Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance
10.1016/j.jacc.2025.09.004 · 2026 · External reference
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy
10.1161/circulationaha.119.045093 · 2020 · External reference
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study
10.1002/ejhf.2027 · 2021 · External reference
Unresolved reference
External reference
Rhabdomyolysis in the Setting of Concomitant Use of Tafamidis, Atorvastatin, and Amiodarone
10.1016/j.jaccas.2020.09.037 · 2020 · External reference
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy
10.1016/j.jacc.2024.11.042 · 2025 · External reference
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
10.1056/nejmoa1716153 · 2018 · External reference
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy
10.1001/jama.2023.18688 · 2023 · External reference
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
10.1056/nejmoa2107454 · 2021 · External reference
Current and Future Treatment Landscape of Transthyretin Amyloid Cardiomyopathy
10.1007/s40119-025-00424-6 · 2025 · External reference
Combination Therapy Versus Monotherapy In Hereditary Transthyretin Amyloidosis
10.1016/j.cardfail.2024.10.407 · 2025 · External reference
